Systematic Review

Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer

A meta-analysis of randomized controlled trials

Li-Yang Wang, MD, Hua Xie, MD, Hang Zhou, MD, Wen-Xiu Yao, PhD, Xin Zhao, MD, Yi Wang, MD.

ABSTRACT

الأهداف: لتقييم فعالية وسلامة العلاج الكيميائي القائم على كاربوبلاتين قبل الجراحة في المرضى الذين يعانون من سرطان الثدي ثلاثي التأثير السلبي (TNBC).

الطريقة: بحثنا بشكل منهجي في تجارب معشاة منضبطة ذات صلة في Web of Science، Cochrane Library، PubMed، EMBASE، التجارب السريرية المسجلة، في مجموعة من ملخصات المؤتمرات الدولية الكبرى. وتضمنت نقطة المنتهى معدلات الاستجابة المرضية كاملة (pCR)، الاستجابة الشاملة (ORR)، جراحة الثدي المحافظة (BCS)، والسمية. تم حساب مجموع الخطر النسبي (RR) لكل نقطة منتهى باستخدام نموذج محدود أو عشوائي التأثير إعتماداً على إختلاف الدراسات المشمولة.

النتائج: شملت 5 تجارب معشاة منضبطة 1007 مريضاً في التحليل التلوي. كان علاج كاربوبلاتين الكيميائي مرتبط بمعدل pCR بنسبة 53.3% وهو أعلى بكثير من المعدل دون العلاج الكيميائي 37.8%، RR: 1.41، 95%CI: 1.23 to 1.62، p<0.00001، بالمقارنة مع عدم استخدام العلاج الكيميائي (48.1%)، زاد علاج الكاربوبلاتين الكيميائي معدل BCS 59.7%، RR: 1.24، 95%CI: 1.06 to 1.46، p=0.007 كان علاج كاربوبلاتين الكيميائي مرتبطاً ب ORR مقارب كما في العلاج من دون الكاربوبلاتين. ارتبط علاج كاربوبلاتين الكيميائي بارتفاع معدلات فقر الدم إلى الدرجة 3 أو 4، قلة العدلات، قلة العدلات الحموية، وقلة الصفيحات من العلاج غير كاربوبلاتين، بينما كانت الحميتين مرتبطة مع حدوث مماثل من الشعور بالتعب، و نقص في كريات الدم البيضاء، و الغثيان/القيء.

الخاتمة: تشير الأدلة المتاحة إلى أفضلية استخدام علاج كاربوبلاتين الكيميائي قبل الجراحة مرتبط بمعدلات pCR و BCS بشكل ملحوظ مقارنة بالعلاج دون الكاربوبلاتين الكيميائي في مرضى TNBC.

Objectives: To evaluate the efficacy and safety of carboplatin-based preoperative chemotherapy in triple-negative breast cancer patients (TNBC).

Methods: PubMed, EMBASE, the Web of Science, the Cochrane Library, major clinical trial registries, and abstract collections from major international meetings were systematically searched for relevant randomized controlled trials. Endpoints included rates of pathologic complete response (pCR), overall response (ORR), breast-conserving surgery (BCS) and toxicity. Pooled relative risk (RR) was calculated for each endpoint using a fixed- or random-effect model depending on the heterogeneity among included studies.

Results: A total of 5 randomized controlled trials involving 1007 patients were included in the meta-analysis. Carboplatin-based chemotherapy was associated with a pooled pCR rate of 53.3%, which was significantly higher than the rate associated with non-carboplatin therapy (37.8%, RR: 1.41, 95% confidence interval [CI]: 1.23 to 1.62, p<0.00001). Compared with non-carboplatin therapy (48.1%), carboplatin-based chemotherapy increased BCS rate (59.7%, RR: 1.24, 95%CI: 1.06 to 1.46, p=0.007). Carboplatin-based chemotherapy was associated with similar ORR as non-carboplatin therapy. Carboplatin-based chemotherapy was associated with higher incidence of grade 3 or 4 anemia, neutropenia, febrile neutropenia, and thrombocytopenia than non-carboplatin therapy, while the 2 regimens were associated with similar incidence of fatigue, leucopenia, and nausea/vomiting.

Conclusion: The available evidence suggests that carboplatin-based preoperative chemotherapy is associated with significantly better pCR and BCS rates than non-carboplatin-based therapy in TNBC patients.

Address correspondence and reprint request to: Dr. Yi Wang, Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. E-mail: 13219055022@163.com

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in females worldwide.[1] Triple-negative breast cancer (TNBC), a subtype of breast cancer accounting for 10-20% of all breast cancers,[2-11] is characterized by absence of expression of estrogen, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). The TNBC occurs predominantly in young people and is associated with higher rates of metastasis and mortality than other subtypes of breast cancer.[2-5] It seems that women with TNBC do not benefit from targeted therapy or endocrine therapy. Preoperative chemotherapy, an important part of an integrated treatment approach, is increasingly used in patients with locally advanced breast cancer. Preoperative chemotherapy has been found to reduce cancer volume, improve the surgical resection rate, reduce the tumor stage, and increase the possibility of breast-conserving surgery.[12] It also allows *in vivo* assessment of patient sensitivity to chemotherapy.[13] Studies suggest that preoperative chemotherapy for breast cancer provides survival benefits comparable with those of postoperative chemotherapy, and that it is associated with significantly higher rates of overall survival (OS) in patients achieving pathologic complete response (pCR).[14] Specifically among patients with TNBC who experience pCR, preoperative chemotherapy is improved 26% of 3-years OS rate.[15] Maximizing the rate of pCR is widely considered the most important outcome for preoperative chemotherapy against TNBC. The 48-70% of breast cancer patients with BRCA1 mutations are TNBC.[16-18] The tumor with BRCA1 mutations may suffer from defects in DNA repair pathways. Thus, platinum-based chemotherapy, although usually a second-line treatment in breast cancer, may be an effective first-line approach in TNBC. Carboplatin is preferable to cisplatin because it shows comparable antitumor activity to cisplatin but with fewer adverse effects. It is unclear on whether carboplatin-based preoperative chemotherapy is effective and safe for patients with TNBC. A small trial in Spain showed that adding carboplatin to preoperative chemotherapy did not improve pCR in patients with basal-like breast cancer,[19] whereas 2 studies in USA and Germany showed that adding the drug to preoperative chemotherapy improved the pCR of patients with TN BC.[20,21] Thus, we performed this meta-analysis of available randomized controlled trials.

Methods. *Search strategy and study inclusion.* We systematically searched PubMed, the Web of Science, EMBASE, and the Cochrane Library for randomized controlled trials published between January 2000-2015 that examined the effectiveness of carboplatin in preoperative chemotherapy against TNBC. Publications were screened initially on the basis of the title and abstract, and then on the basis of the full text.

We also searched major clinical trial registries (www.ClinicalTrials.gov, www.who.int/trialsearch) for relevant randomized controlled trials. The abstracts of annual meetings of the San Antonio Breast Cancer Symposium, American Society of Clinical Oncology and European Society for Medical Oncology were searched.

No language restrictions were applied during any searches. To be included in the meta-analysis, studies had to: 1) involve patients who had been diagnosed with TNBC based on pathology, who did not suffer any other diseases and who were undergoing their first treatment; 2) compare carboplatin-based and non-carboplatin preoperative chemotherapy; and 3) report sufficient outcomes data.

Two authors independently searched all potentially relevant publications. Discrepancies were resolved by discussion.

Data extraction. Two authors independently extracted data from the included studies using a standard form. The following data were extracted from each study: 1) basic characteristics, including authors, year of publication, and phase of the trial; 2) study characteristics, including number of subjects enrolled, patient ages, disease stages, and chemotherapy regimens; 3) outcomes of interest: pCR, overall response (ORR), and breast-conserving surgery (BCS); 4) types and incidence of grade 3 or 4 adverse events.

Assessment of study quality. The methodological quality of the included studies was assessed using Review Manager 5.3 (www.cochrane.org).

Statistical analysis. The primary endpoint was pCR rate, and secondary endpoints included ORR, rate of BCS, and rates of grade 3 or 4 adverse events. The ORR was defined as the sum of partial and complete response rates according to the guidelines for response evaluation criteria in solid tumors.[22] Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0 or 4.0.

Relative risk (RR) and associated 95% confidence intervals (CI) were estimated for data using the Mantel-Haenszel fixed-effect model or the Der Simonian-Laird random-effect model. The fixed-effect model was used when significant heterogeneity was absent across the

pooled studies; significant heterogeneity was considered to exist when the Q test gave an associated *p*-value <0.05 and I2 was >60%. Otherwise, the random-effect model was used.

All statistical analyses were performed using Review Manager 5.3. All *p*-values were calculated for a 2-tailed distribution.

Results. *Characteristics of included studies.* A total of 65 potentially eligible trials were screened. Finally, 5 independent trials, involving altogether 1007 patients, were included in the meta-analysis[19-21,23,24]


Figure 1 - Flow chart diagram of study selection. RCT - randomized controlled trials

(**Figure 1**, **Table 1**). The 5 randomized controlled trials included between 91 and 595 TNBC patients in stages I-III; 3 trials involved Caucasians, and the other 2 involved Asians. All 5 studies examined preoperative chemotherapy comprising a combination of carboplatin with another taxane chemotherapeutic, including paclitaxel and docetaxel. We evaluated the quality of 4 publications with full-text. All 4 studies completely described the randomization procedure, adequate allocation concealment, and complete results.

Pathologic complete response. All 5 trials described data on pCR. The absolute pCR rate was 53.3% (272/510) in patients receiving carboplatin-based therapy and 37.8% (188/497) in patients receiving non-carboplatin therapy. No significant heterogeneity in pCR rate data was detected among studies (I2=56%, *p*=0.06). This RR indicated a significantly better rate for carboplatin therapy (RR: 1.41, 95%CI: 1.23 to 1.62, *p*<0.00001) (**Figure 2**).

Overall response. Two of the 5 studies reported ORR data.[19,24] No significant heterogeneity was observed for this outcome among the 3 studies (I2=0%, *p*=0.89). The RR showed a slight benefit of carboplatin-based preoperative chemotherapy over non-carboplatin therapy, but the difference in ORR was not significant (RR: 1.11, 95%CI: 0.96 to 1.29, *p*=0.16) (**Figure 3**).

Breast-conserving surgery. Breast-conserving surgery data were reported in 2 of 5 trials.[19,20] No significant heterogeneity was observed among studies (I2=27%, *p*=0.24). The absolute BCS rate was 59.7% in carboplatin-based chemotherapy comparison with 48.1% in non-carboplatin therapy. The RR showed significant difference in BCS rate between carboplatin-based and non-carboplatin-based therapy (RR: 1.24, 95%CI: 1.06 to 1.46, *p*=0.007) (**Figure 4**).

Table 1 - Characteristics of randomized controlled trials in the meta-analysis.

Study	No. patients	Study type	Disease stage	Treatment schedule	pCR with CBP	pCR without CBP
					(%)	
Alba et al[19] 2012	93	phase 2	I-III	EPI+CTX×4 cycles→TXT×4 cycles vs EPI+CTX×4 cycles→TXT+ CBP×4 cycles	29.8	34.8
Ando et al[23] 2014	75	phase 2	I-IIIa	CBP and wPTX ×4 cycles→CEF ×4 cycles vs wPTX ×4 cycles→CEF×4 cycles	62.2	26.3
Sikov et al[20] 2014	433	prospective series	II-III	wPTX×12 cycles→TXT+CTX+CBP q14×4 cycles vs wPTX×12cycles→TXT+CTX×4 cycles	60.2	46.2
Von minckwitz et al[21] 2014	315	phase 2	II-III	CBP+wPTX+non-PEGylated liposomal doxorubicin +Bev×18w vs wPTX+non-PEGylated liposomal doxorubicin+Bev×18w	53.2	36.9
Zhang et al[24] 2013	91	phase 2	II-III	CBP+PTX ×4-6 cycles vs EPI+PTX×4-6cycles	38.3	13.6

EPI - epirubicin, CTX - cyclophosphamide, CBP - carboplatin, DOC - docetexel, PTX - paclitaxel, wPTX - weekly paclitaxel, CEF - cyclophosphamide, epirubicin, and 5-fluorouracil, pCR - pathological complete response, Bev - bevacizumab, vs - versus

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Alba E/2012	14	47	16	46	8.5%	0.86 [0.47, 1.55]
Ando M/2014	23	37	10	38	5.2%	2.36 [1.31, 4.25]
Sikov WM/2014	133	221	98	212	52.5%	1.30 [1.09, 1.56]
von minckwitz G/2014	84	158	58	157	30.5%	1.44 [1.12, 1.85]
Zhang P/2013	18	47	6	44	3.3%	2.81 [1.23, 6.42]
Total (95% CI)		510		497	100.0%	1.41 [1.23, 1.62]
Total events	272		188			

Heterogeneity: Chi² = 9.13, df = 4 (P = 0.06); I² = 56%
Test for overall effect: Z = 4.90 (P < 0.00001)

Figure 2 - Forest plot of pathologic complete response rate for carboplatin-based relative to non-carboplatin-based preoperative chemotherapy. M-H - Mantel-Haenszel test, CI - confidence interval

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Alba E/2012	36	47	32	46	47.2%	1.10 [0.86, 1.41]
Zhang P/2013	42	47	35	44	52.8%	1.12 [0.94, 1.34]
Total (95% CI)		94		90	100.0%	1.11 [0.96, 1.29]
Total events	78		67			

Heterogeneity: Chi² = 0.02, df = 1 (P = 0.89); I² = 0%
Test for overall effect: Z = 1.39 (P = 0.16)

Figure 3 - Forest plot of overall response for carboplatin-based relative to non-carboplatin-based preoperative chemotherapy. M-H - Mantel-Haenszel test, CI - confidence interval

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Alba E/2012	34	47	31	46	24.8%	1.07 [0.82, 1.40]
Sikov WM/2014	126	221	93	212	75.2%	1.30 [1.07, 1.57]
Total (95% CI)		268		258	100.0%	1.24 [1.06, 1.46]
Total events	160		124			

Heterogeneity: Chi² = 1.37, df = 1 (P = 0.24); I² = 27%
Test for overall effect: Z = 2.69 (P = 0.007)

Figure 4 - Forest plot of breast-conserving surgery rate for carboplatin-based relative to non-carboplatin-based preoperative chemotherapy. M-H - Mantel-Haenszel test, CI - confidence interval

Figure 5 - Funnel plot for publication bias in pathologic complete response analysis. SE - standard error, RR - relative risk

Safety. Patients who received carboplatin-based therapy showed significantly higher incidence of the following adverse events than patients who received non-carboplatin therapy: grade 3 or 4 anemia (*p*=0.01), neutropenia (*p*<0.00001), febrile neutropenia (*p*=0.03), and thrombocytopenia (*p*<0.00001). In contrast, both types of preoperative chemotherapy were associated with similar incidence of grade 3 or 4 fatigue (*p*=0.52), leucopenia (*p*=0.09), and nausea/vomiting (*p*=0.35).

Publication bias. Publication bias was not found according to funnel plot for pCR (**Figure 5**). For ORR, BCS and safety analysis, it was inappropriate to evaluate the publication bias, since the lack of data provided.

Discussion. Our meta-analysis aimed to assess evidence available from randomized controlled trials, suggest that carboplatin-based therapy is associated with significantly greater pCR and BCS rate than non-carboplatin therapy. To our knowledge, this is the first meta-analysis to evaluate the efficacy and safety of carboplatin-based preoperative chemotherapy for patients with TNBC. One meta-analyses while evaluated the value of platinum-based chemotherapy in TNBC, revealed that platinum-based preoperative chemotherapy significantly increase pCR rate in TNBC patients compared with containing no platinum drugs.[25] The results of our meta-analysis further demonstrated that the addition of carboplatin to the preoperative chemotherapy regimen significantly increased pCR rate in TNBC patients. The conclusion on pCR of another meta-analyses[26] regardng carboplatin and bevacizumab is in agreement with us. However, we newly found carboplatin can improve the BCS, but we evaluate the safety.

Preoperative chemotherapy for TNBC may be even more effective when conducted in the presence of antiangiogenic chemotherapy. In the GeparQuinto trial, while the pCR was evaluated in TNBC after neoadjuvant chemotherapy with or without bevacizumab; pCR was higher in adding bevacizumab (p=0.003).[27] In another study, the addition of bevacizumab to neoadjuvant therapy was found to increase pCR rate in patients in early stages of triple-negative and HER2-positive breast cancer.[21] At the same time, preoperative chemotherapy with bevacizumab may affect surgical incision healing. None of the studies in our meta-analysis examined bevacizumab, highlighting the need to assess this treatment in TNBC patients.

Preoperative chemotherapy may be used to slow tumor growth and thereby facilitate surgical resection. At the same time, such chemotherapy perhaps increases the risk of surgical complications. Our meta-analysis suggests that adding carboplatin to such chemotherapy significantly increases the incidence of grade 3 or 4 anemia, neutropenia, febrile neutropenia, and thrombocytopenia. We conclude from the available evidence that the toxic effects of preoperative chemotherapy exert only minor effects on the subsequent surgery.

This meta-analysis suffers from several limitations. First, the small number of randomized controlled trials and study subjects may affect the statistical power and reliability of our meta-analysis. In addition, not all trials reported data on all relevant outcomes. Second, our meta-analysis was based on aggregate rather than individual patient data, which can lead to higher efficacy estimates.[28] Third, our meta-analysis evaluated the efficacy of carboplatin combined with taxanes, so the findings may not be relevant to other chemotherapy regimens. This meta-analysis cannot answer the question of which chemotherapy regimen is the best choice for TNBC. Fourth, the pCR definition in the included studies was completely the same, which may lead to certain heterogeneity.

In conclusion, our meta-analysis of available evidence from randomized controlled trials suggests that carboplatin-based preoperative chemotherapy leads to significantly higher pCR and BCS rate in TNBC patients than non-carboplatin therapy. Further large-scale, prospective, randomized, controlled clinical trials are required to investigate the survival benefits from carboplatin-based preoperative chemotherapy in TNBC patients.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; 61: 69-90.
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res* 2007; 13(15 Pt 1): 4429-4434.
3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer* 2007; 109: 1721-1728.
4. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer--current status and future directions. *Ann Oncol* 2009; 20: 1913-1927.
5. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. *J Clin Oncol* 2006; 24: 5652-5657.
6. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. *Lancet Oncol* 2007; 8: 235-244.
7. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. *Clin Cancer Res* 2008; 14: 1368-1376.
8. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. *Cancer* 2012; 118: 5463-5472.
9. Yuan N, Meng M, Liu C, Feng L, Hou L, Ning Q, et al. Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. *Mol Clin Oncol* 2014; 2: 245-251.
10. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. *Cancer* 2007; 109: 25-32.
11. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. *BMC Cancer* 2007; 7: 134.

12. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. *J Clin Oncol* 2008; 26: 786-790.

13. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. *J Clin Oncol* 1998; 16: 2672-2685.

14. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. *Cochrane Database Syst Rev* 2007; (2): CD005002.

15. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol* 2008; 26: 1275-1281.

16. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. *J Clin Oncol* 2011; 29: 4373-4380.

17. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. *Clin Cancer Res* 2005; 11: 5175-5180.

18. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. *J Natl Cancer Inst* 2003; 95: 1482-1485.

19. Alba E, Chacon JI, Lluch A, Anton A, Estevez L, Cirauqui B, et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. *Breast Cancer Res Treat* 2012; 136: 487-493.

20. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/ or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). *J Clin Oncol* 2015: 33: 13-21.

21. Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol* 2014; 15: 747-756.

22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000; 92: 205-216.

23. Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/ epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. *Breast Cancer Res Treat* 2014; 145: 401-409.

24. Zhang P, Yin Y, Xu B, Wang X, Zhang B, Li Q, et al. Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer: a phase II clinical trial. *San Antonio Breast Cancer Symposium* 2013; 73.

25. Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, et al. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. *Breast Cancer Res Treat* 2014; 144: 223-232.

26. Chen XS, Yuan Y, Garfield DH, Wu J, Huang O, Shen KW. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. *PloS One* 2014; 9: e108405.

27. Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). *Ann Oncol* 2013; 24: 2978-2984.

28. Qi WX, Wang Q, Jiang YL, Sun YJ, Tang LN, He AN, et al. Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data. *PloS One* 2013; 8: e55637.